Herborium Group, Inc. (OTCMKTS:HBRM) Enters The Hispanic Market
Herborium Group, Inc. (OTCMKTS:HBRM) a botanical therapeutics® firm and the provider of unique botanical medical products that target dermatological concerns such as acne and other wellness and health issues reported that the firm’s most established brand ‘AcnEase®’ has been introduced in the $1.4 trillion U.S. Hispanic Market.
The Hispanic market is both personal care conscious and e-commerce savvy. Cultural and educational gains made this market a prominent part of the U.S. and world economy, forming more than 15% of the U.S. e-commerce industry. AcnEase is an ideal offering for a market that favors natural offerings. Hispanic purchasing power has surged at a compound yearly growth rate of 7.5%, which is almost twice as fast as the growth rate in the total United States.
The response of the new industry to AcnEase is both very strong and immediate. The recently open Spanish language site, and Herborium introduced a Spanish Language Social Media plan and gained the immediate focus of the international Spanish language industry. Orders are coming in from Argentina, Spain and Mexico, and two key Spanish language influencers, Nury and Amanda Chic, are now a part of the campaign.
Herborium anticipates to triple its Hispanic Industry outreach this year. It will have a robust impact on supporting the firm revenues, launching new offerings and profitability, and accelerating the firm’s ability to achieve other strategic objectives. Dr. Agnes P. Olszewski, the CEO, confirmed the firm’s commitment to up-list and to effort towards enhancing shareholder value.
Herborium Group is a botanical therapeutics® firm that licenses, markets and develops proprietary, botanical based medical products to healthcare professionals and consumers. The firm’s business model moves around emerging market opportunities led by the growth of a new industry sector based between high-risk, high-cost, commoditized classic nutraceuticals and ethical pharmaceuticals. The firm uses clinical substantiation and a proactive regulatory plan depending on the FDA Guidance for Industry.© Copyright 2016 OTC News Magazine. All rights reserved.